HLA-DR15-specific inhibition attenuates autoreactivity to the Goodpasture antigen.


Journal

Journal of autoimmunity
ISSN: 1095-9157
Titre abrégé: J Autoimmun
Pays: England
ID NLM: 8812164

Informations de publication

Date de publication:
09 2019
Historique:
received: 19 02 2019
revised: 03 05 2019
accepted: 04 05 2019
pubmed: 21 5 2019
medline: 22 8 2020
entrez: 21 5 2019
Statut: ppublish

Résumé

Goodpasture's disease manifests as rapidly progressive glomerulonephritis. Current immunosuppressive treatments do not specifically target the pathological immune response and have significant side effects. Like most autoimmune diseases, the strongest genetic association is with the HLA alleles. Inheritance of HLA-DR15 confers susceptibility, and structure-function studies have shown that HLA-DR15 plays a causative role in activating autoreactive pro-inflammatory T cells. Thus, specific inhibition of HLA-DR15 would provide a targeted therapeutic approach. We hypothesised that PV-267, an HLA-DR15-specific inhibitor, would effectively block HLA-DR15 presentation of the dominant epitope, attenuate the activation of autoreactive T cells, and limit disease. Using humanised HLA-DR15 transgenic mice, α3

Identifiants

pubmed: 31104947
pii: S0896-8411(18)30665-6
doi: 10.1016/j.jaut.2019.05.004
pii:
doi:

Substances chimiques

Autoantigens 0
Collagen Type IV 0
Fcgr2b protein, mouse 0
HLA-DR Serological Subtypes 0
HLA-DR15 antigen 0
Peptides 0
Receptors, IgG 0
type IV collagen alpha3 chain 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102276

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Megan Huynh (M)

Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, 3168, Australia.

Peter J Eggenhuizen (PJ)

Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, 3168, Australia.

Gary L Olson (GL)

Provid Pharmaceuticals, Monmouth Junction, NJ, 08852, USA.

N Bhaskara Rao (NB)

Provid Pharmaceuticals, Monmouth Junction, NJ, 08852, USA.

Christopher R Self (CR)

Provid Pharmaceuticals, Monmouth Junction, NJ, 08852, USA.

Yanjun Sun (Y)

Provid Pharmaceuticals, Monmouth Junction, NJ, 08852, USA.

Stephen R Holdsworth (SR)

Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, 3168, Australia; Dept. of Nephrology, Monash Health, Clayton, Victoria, 3168, Australia.

A Richard Kitching (AR)

Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, 3168, Australia; Dept. of Nephrology, Monash Health, Clayton, Victoria, 3168, Australia; Dept. of Paediatric Nephrology, Monash Health, Clayton, Victoria, 3168, Australia.

Joshua D Ooi (JD)

Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, 3168, Australia. Electronic address: joshua.ooi@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH